Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvalent, Inc. - Class A Common Stock (NQ:NUVL)

101.69 -5.13 (-4.80%)
Streaming Delayed Price Updated: 3:14 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvalent, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
Why Did Nuvalent Stock Surge 15% Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Why Nuvalent (NUVL) Shares Are Down 6% Today ↗
Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each. 
Via Benzinga
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
NUVL Stock Earnings: Nuvalent Misses EPS for Q2 2024 ↗
NUVL stock results show that Nuvalent missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer ↗
Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial. 
Via Benzinga
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer ↗
Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug. 
Via Investor's Business Daily
News headline image
Wondering what's happening in today's after-hours session? ↗
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
This Waste Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Nuvalent (NUVL) Q2 R&D Up 65% ↗
Via The Motley Fool
News headline image
Nuvalent Inc-A (NASDAQ:NUVL) Reports Q2 2025 Earnings Miss with Focus on Oncology Pipeline Progress ↗
Nuvalent (NUVL) reported Q2 2025 EPS of -$1.31, slightly missing estimates, with no revenue as expected. Shares rose pre-market as investors focus on its oncology pipeline, including zidesamtinib's NDA... 
Via Chartmill
Topics Earnings
News headline image
Nuvalent Touts 'Positive' Data From Zidesamtinib Trial For Pretreated Patients With Advanced Form Of Lung Cancer ↗
Nuvalent releases pivotal ARROS-1 trial data and plans to begin a rolling NDA submission for zidesamtinib in July 2025. 
Via Benzinga
News headline image
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday ↗
 
Via Benzinga
News headline image
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
News headline image
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
News headline image
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity ↗
Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in... 
Via Benzinga
News headline image
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths ↗
Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test. 
Via Investor's Business Daily
Topics Death
News headline image
Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗
 
Via Benzinga
News headline image
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio? ↗
 
Via Benzinga
News headline image
3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally ↗
Although short-squeeze stocks to buy present great risk, betting against the bears can also yield dramatically robust returns. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.